Public Summary

Summary for ARTG Entry:	153016	B Sustained Release
ARTG entry for	Medicine Listed	
Sponsor	Herbs of Gold Pty Ltd	
Postal Address	PO Box 3143, KIRRAWEE, NSW, 2232 Australia	
ARTG Start Date	11/06/2008	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . B Sustained Release

Product Type	Single Medicine Product	**Effective Date**	11/11/2019

Permitted Indications

Antioxidant/Reduce free radicals formed in the body
Helps convert (state food) into energy
Maintain/support energy production
Maintain/support general health and wellbeing
Aid/assist healthy red blood cell production
Maintain/support red blood cell health
Maintain/support blood health
Helps maintain/support haemoglobin formation/synthesis
Maintain/support cardiovascular system health
Aid/assist/helps glucose/sugar/carbohydrate metabolism
Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)
Support healthy stress response in the body
Aid/assist/helps synthesis of neurotransmitters
Maintain/support nervous system health
Maintain/support nervous system function
Help to prevent neural tube defects such as spina bifida and/or anencephaly
Maintain/support skin health

Indication Requirements

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must not imply or refer to serious cardiovascular conditions.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Indication can only be used for medicines that contain folic acid as an active ingredient and the recommended daily dose of the medicine provides a minimum of 400 micrograms of folic acid. Product presentation referring to the prevention of neural tube defects must include at least one of the following label statements: when trying to conceive and during the first trimester of pregnancy, and/or when taken at least four weeks before conception and during the first trimester of pregnancy.

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

If directed to women, Label statement: Advise your doctor of any medicine you take during pregnancy, particularly in your first trimester.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule

Components

1 . Formulation 1

Dosage Form	Tablet, modified release
Route of Administration	Oral
Visual Identification	

Active Ingredients

ascorbic acid	**200 mg**
Biotin	**50 microgram**
calcium pantothenate	**120 mg**
Equivalent: pantothenic acid	109.9 mg
choline bitartrate	**50 mg**
cyanocobalamin	**100 microgram**
folic acid	**400 microgram**
inositol	**50 mg**
nicotinamide	**100 mg**
pyridoxine hydrochloride	**75 mg**
Equivalent: pyridoxine	61.7 mg
riboflavin	**80 mg**
thiamine hydrochloride	**100 mg**

Other Ingredients (Excipients)

Carnauba Wax
ethylcellulose
glyceryl behenate
hypromellose
iron oxide yellow
macrogol 8000
magnesium stearate
microcrystalline cellulose
silicon dioxide

Public Summary

titanium dioxide

Public Summary